A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration | MicrobiomeTrials← Back to trialsNCT04201457
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2020-01-17Est. Completion: 2026-10-01
Enrollment target: 57 participants Locations- Phoenix Children's Hospital, Phoenix, Arizona, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- University of Florida, Gainesville, Florida, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
- National Cancer Institute Pediatric Oncology Branch, Bethesda, Maryland, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Cincinnati Children Hospital Medical Center, Cincinnati, Ohio, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
- St. Jude Children Research Hospital, Memphis, Tennessee, United States
- Texas Children's Cancer Center, Houston, Texas, United States